{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/post-herpetic-neuralgia/prescribing-information/lidocaine-plasters/","result":{"pageContext":{"chapter":{"id":"3b69fe1d-39be-5060-a4c5-001c53ce1c70","slug":"lidocaine-plasters","fullItemName":"Lidocaine plasters","depth":2,"htmlHeader":"<!-- begin field b69c65eb-cb5b-483f-b490-a73c011fadea --><h2>Lidocaine plasters</h2><!-- end field b69c65eb-cb5b-483f-b490-a73c011fadea -->","summary":"","htmlStringContent":"<!-- begin item 78c6954e-4760-4fb3-9c81-a73c011fac48 --><!-- end item 78c6954e-4760-4fb3-9c81-a73c011fac48 -->","topic":{"id":"54614fe0-8a47-5df0-b8e9-67d6417eac0d","topicId":"42508b4e-7987-4ff7-9cd1-647315a678b7","topicName":"Post-herpetic neuralgia","slug":"post-herpetic-neuralgia","lastRevised":"Last revised in July 2017","chapters":[{"id":"b4e97191-f5f0-5efa-bc32-1a8739fb0524","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a657749a-6629-5da1-bf22-9d164969ca93","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"36c8e1f0-287e-5380-bc4f-f42ddf04e983","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f8c609d4-05b5-538c-b9c6-d643d7e7f5e8","slug":"changes","fullItemName":"Changes"},{"id":"92f79bd2-9e70-52dd-b404-510400482111","slug":"update","fullItemName":"Update"}]},{"id":"addbece3-3dce-55c5-83b0-bd2fdd225c1f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"a3192eb2-159a-5ddf-82bf-24a9364207ee","slug":"goals","fullItemName":"Goals"},{"id":"4f386102-bf02-582c-9139-eb6d81f97852","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"9b2dd798-4f3c-5194-a525-6fd005d0e2d3","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e4d6aaad-13cc-5127-b315-04879ba584e5","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"6384851a-a5ee-56c3-ae26-accd5a02bda2","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f1189ae3-2db8-502c-aa1f-3de86bbd0aec","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"11d0f24e-273c-5602-a2a2-c1f9b6afb8fd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e8bc827a-09c6-5d81-b648-e6aab18f479a","slug":"definition","fullItemName":"Definition"},{"id":"7d11ac85-acf6-5480-a72d-baaa197a6cd0","slug":"prevalence","fullItemName":"Prevalence"},{"id":"bcc711bf-9832-566c-86d0-a73e6f90ec7c","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"59f87b98-5214-5e7d-9f01-6ee75d527557","slug":"prognosis","fullItemName":"Prognosis"},{"id":"bbcea3ba-c2de-5140-8aa3-38794493bac7","slug":"complications","fullItemName":"Complications"}]},{"id":"d9de53aa-a485-59fd-890b-c2e883790326","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4106210e-2a16-5414-a10f-2e6f04295872","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"f6decb43-bacd-5d0d-bf99-39695913260e","fullItemName":"Management","slug":"management","subChapters":[{"id":"8de90f5c-0670-56d7-b5c7-dd38335fe889","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"6932895c-9dfd-5da5-a4dd-cba579bf4edd","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"75ab84b5-9461-5828-a2ca-b50bf9f35cc0","slug":"neuropathic-pain-treatments","fullItemName":"Neuropathic pain treatments"},{"id":"e7ce9ec1-b3a2-5b78-a4e1-2e41055c4dcd","slug":"paracetamol-codeine","fullItemName":"Paracetamol and codeine"},{"id":"3b69fe1d-39be-5060-a4c5-001c53ce1c70","slug":"lidocaine-plasters","fullItemName":"Lidocaine plasters"}]},{"id":"53bc33fd-0728-532f-a15f-1caa6952c0f9","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"8aa7ebb2-f0d7-5611-9ea0-3ed478028b44","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"7e4288c2-3520-5856-bcd6-efe055368823","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c99e378c-55fa-5f4e-9bc3-33949142e857","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"f1d65c20-04ce-5fa3-a7a4-dfc340714178","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"fd48516c-88c8-51e3-b7f9-231b96ff1bce","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"28d25826-2b2a-5f6f-822b-598bd4997c64","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0aa7c920-194e-5c04-ae6a-32f5ef3734ec","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"6932895c-9dfd-5da5-a4dd-cba579bf4edd","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"3d0b9136-7fc1-5ae2-b863-49c692af0a46","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field 20623b2a-d6b2-497c-82e6-a73c0122d7b1 --><h3>Dose</h3><!-- end field 20623b2a-d6b2-497c-82e6-a73c0122d7b1 -->","summary":"","htmlStringContent":"<!-- begin item 1049200d-1895-4cf0-8220-a73c0122d24b --><!-- begin field 100ce98f-aedc-4801-b8f3-a73c0122d7b1 --><ul><li>The painful area should be covered with a plaster once daily for up to 12 hours within a 24 hours period. Only the number of plasters that are needed for an effective treatment should be used.<ul><li>When needed, the plasters may be cut into smaller sizes with scissors prior to removal of the release liner.</li><li>No more than three plasters should be used at the same time.</li></ul></li><li>Each plaster must be worn for no longer than 12 hours. The subsequent plaster-free interval must be at least 12 hours.</li><li>Treatment outcome should be re-evaluated after 2-4 weeks. If there has been no response after this period, treatment must be discontinued as potential risks may outweigh benefits.<ul><li>Long-term use in clinical studies showed that the number of plasters used decreased over time. Therefore treatment should be reassessed at regular intervals to decide whether the amount of plasters needed to cover the painful area can be reduced, or if the plaster-free period can be extended.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/post-herpetic-neuralgia/references/\">ABPI, 2015</a>]</p><!-- end field 100ce98f-aedc-4801-b8f3-a73c0122d7b1 --><!-- end item 1049200d-1895-4cf0-8220-a73c0122d24b -->","subChapters":[]},{"id":"f49d5357-fac2-5063-a143-7ced04c56d21","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field a7d70a1a-043f-4277-ae4d-a73c0122bdd0 --><h3>Adverse effects</h3><!-- end field a7d70a1a-043f-4277-ae4d-a73c0122bdd0 -->","summary":"","htmlStringContent":"<!-- begin item 6025633f-f146-414f-92ff-a73c0122bb6e --><!-- begin field 761807cf-8ff7-4520-9c87-a73c0122bdd0 --><p>The most common adverse effects of lidocaine plasters are application site reactions, including burning, dermatitis, erythema, pruritus, rash, skin irritation, and vesicles.</p><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/post-herpetic-neuralgia/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/post-herpetic-neuralgia/references/\">BNF 72, 2016</a>]</p><!-- end field 761807cf-8ff7-4520-9c87-a73c0122bdd0 --><!-- end item 6025633f-f146-414f-92ff-a73c0122bb6e -->","subChapters":[]},{"id":"05137fe2-1e4f-5b5b-9ab7-15e1f1c7f66c","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 82aa9882-1b9b-48dd-9aa2-a73c0122a323 --><h3>Contraindications and cautions</h3><!-- end field 82aa9882-1b9b-48dd-9aa2-a73c0122a323 -->","summary":"","htmlStringContent":"<!-- begin item e91dfe17-f502-4b8b-9f88-a73c0122a0ac --><!-- begin field 600f76a1-c4c2-435e-8952-a73c0122a323 --><ul><li>Do not prescribe lidocaine plasters to people with known hypersensitivity to other local anaesthetics of the amide type e.g. bupivacaine, etidocaine, mepivacaine and prilocaine.<ul><li>The plaster must not be applied to inflamed or injured skin, such as active herpes zoster lesions, atopic dermatitis, or wounds.</li></ul></li><li>Prescribe lidocaine plasters with caution to people with severe cardiac, renal, or hepatic impairment.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/post-herpetic-neuralgia/references/\">ABPI, 2015</a>]</p><!-- end field 600f76a1-c4c2-435e-8952-a73c0122a323 --><!-- end item e91dfe17-f502-4b8b-9f88-a73c0122a0ac -->","subChapters":[]},{"id":"68932957-4610-50a4-a1ff-689e533cb941","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field a06eb6e2-9706-4aeb-b755-a73c0122f4c0 --><h3>Drug interactions</h3><!-- end field a06eb6e2-9706-4aeb-b755-a73c0122f4c0 -->","summary":"","htmlStringContent":"<!-- begin item d9f7f34f-dc70-49f4-a2e4-a73c0122f2a1 --><!-- begin field 32cef82c-c2e6-454b-a52a-a73c0122f4c0 --><ul><li>No clinically relevant interactions have been observed in clinical studies with lidocaine plasters.</li><li>The manufacturer states that since the maximum lidocaine plasma concentrations observed in clinical trials with the plaster were low, clinically relevant pharmacokinetic interactions are unlikely.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/post-herpetic-neuralgia/references/\">ABPI, 2015</a>]</p><!-- end field 32cef82c-c2e6-454b-a52a-a73c0122f4c0 --><!-- end item d9f7f34f-dc70-49f4-a2e4-a73c0122f2a1 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}